Romosozumab
- Generic Name
- Romosozumab
- Brand Names
- Evenity 210 Mg Dose, Evenity
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 909395-70-6
- Unique Ingredient Identifier
- 3VHF2ZD92J
- Background
Romosozumab is a humanized monoclonal antibody indicated for the treatment of osteoperosis in postmenopausal women at high risk of fracture and patients who have failed in other treatments or are intolerant to other osteoperosis therapies. Romosozumab prevents bone resorption and induces the formation of bone though it is associated with an increased risk of...
- Indication
Romosozumab is indicated for the treatment of osteoporosis in post menopausal women at high risk of fractures and also in patients with osteoperosis who are intolerant to other treatments or who have failed in other treatments.
- Associated Conditions
- Osteoporosis
- Associated Therapies
- -
Romosozumab Use to Build Skeletal Integrity
- Conditions
- Interventions
- First Posted Date
- 2021-09-28
- Last Posted Date
- 2023-09-11
- Lead Sponsor
- Susan L. Greenspan
- Target Recruit Count
- 200
- Registration Number
- NCT05058976
- Locations
- 🇺🇸
UPMC Senior Communities, Pittsburgh, Pennsylvania, United States
Anabolic Therapy in Postmenopausal Osteoporosis
- Conditions
- Interventions
- First Posted Date
- 2021-08-18
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 50
- Registration Number
- NCT05010590
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
Romosozumab in Women With Chronic SCI
- Conditions
- Interventions
- First Posted Date
- 2021-01-14
- Last Posted Date
- 2024-07-15
- Lead Sponsor
- Northwestern University
- Target Recruit Count
- 12
- Registration Number
- NCT04708886
- Locations
- 🇺🇸
Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States
Evaluation of Romosozumab vs. Zoledronic Acid Effect in Patients With Spinal Cord Injury and Low Bone Mineral Density
- Conditions
- Interventions
- First Posted Date
- 2020-10-22
- Last Posted Date
- 2020-10-22
- Lead Sponsor
- Sheba Medical Center
- Target Recruit Count
- 30
- Registration Number
- NCT04597931
Study to Evaluate Romosozumab in Children and Adolescents With Osteogenesis Imperfecta
- Conditions
- Interventions
- First Posted Date
- 2020-09-11
- Last Posted Date
- 2024-04-15
- Lead Sponsor
- Amgen
- Target Recruit Count
- 25
- Registration Number
- NCT04545554
- Locations
- 🇬🇷
General Children Hospital Panagioti and Aglaias Kyriakou, Athens, Greece
🇮🇹IRCCS Ospedale Pediatrico Bambino Gesu, Roma, Italy
🇹🇷Koc Universitesi Hastanesi, Istanbul, Turkey
Romosozumab to Improve Bone Mineral Density and Architecture in Chronic SCI
- Conditions
- Interventions
- First Posted Date
- 2020-01-18
- Last Posted Date
- 2024-05-10
- Lead Sponsor
- VA Office of Research and Development
- Target Recruit Count
- 36
- Registration Number
- NCT04232657
- Locations
- 🇺🇸
James J. Peters VA Medical Center, Bronx, NY, Bronx, New York, United States
🇺🇸Kessler Institute for Rehabilitation, West Orange, New Jersey, United States
Romosozumab Versus Denosumab for Osteoporosis in Long-term Glucocorticoid Users
- First Posted Date
- 2019-09-16
- Last Posted Date
- 2023-11-22
- Lead Sponsor
- Tuen Mun Hospital
- Target Recruit Count
- 70
- Registration Number
- NCT04091243
- Locations
- 🇨🇳
Tuen Mun Hospital, Hong Kong, China
A Safety and Efficacy Study to Evaluate Romosozumab (AMG 785) in South Korean Women With Osteoporosis
- First Posted Date
- 2016-06-06
- Last Posted Date
- 2019-10-07
- Lead Sponsor
- Amgen
- Target Recruit Count
- 67
- Registration Number
- NCT02791516
- Locations
- 🇰🇷
Research Site, Suwon-si, Gyeonggi-do, Korea, Republic of
Efficacy, Safety and Tolerability of Romosozumab in the Treatment of Japanese Women With Postmenopausal Osteoporosis
- Conditions
- Interventions
- First Posted Date
- 2013-11-25
- Last Posted Date
- 2019-03-25
- Lead Sponsor
- Amgen
- Target Recruit Count
- 252
- Registration Number
- NCT01992159
- Locations
- 🇯🇵
Research Site, Toshima-ku, Tokyo, Japan
Study of Romosozumab (AMG 785) Administered to Healthy Participants and Patients With Stage 4 Renal Impairment or Stage 5 Renal Impairment Requiring Hemodialysis
- First Posted Date
- 2013-04-17
- Last Posted Date
- 2022-07-22
- Lead Sponsor
- Amgen
- Target Recruit Count
- 24
- Registration Number
- NCT01833754
- Locations
- 🇺🇸
Research Site, Orangeburg, South Carolina, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.